Screening people with smoldering multiple myeloma for early amyloidosis
Checks for early light-chain amyloidosis in adults 40 or older with smoldering myeloma.
Key facts
- Who runs it
- Tufts Medical Center
- Where
- Birmingham, Boston, Charlotte, Columbus, Dallas, Durham, Los Angeles, New York, Richmond, Salt Lake City, San Francisco, and Weston, United StatesSee the 13 sites
- Trial code
- Registry title
- Screening for AL Amyloidosis in Smoldering Multiple Myeloma
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 1 May 2024
- Expected to end
- 27 Feb 2029
- Type of study
- Observational
- Record updated
- 26 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older with smoldering multiple myeloma or a monoclonal gammopathy. It checks for light-chain (AL) amyloidosis before symptoms start.
- Age
- 40 years and older
- Sex
- All sexes can join.
- Disease stage
- Smoldering multiple myeloma or a monoclonal gammopathy.
- Biomarker or test result
- dFLC greater than 23 mg/L and an abnormal FLC ratio. If eGFR is less than 50 mL/min/1.73m2, only age and dFLC count.
Main reasons for not taking part
- Younger than 40 years
- Amyloid found in an earlier biopsy
- Adults unable to consent, including the cognitively impaired
- Pregnant women and minors
- Wards of the state and prisoners
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients 40 years of age and older
- diagnosed with either Smoldering Multiple Myeloma or a Monoclonal Gammopathy
- dFLC greater than 23 mg/L
- abnormal FLC ratio
- If the patient has an eGFR less than 50 mL/min/1.73m2, the FLC ratio is inconsequential. The patient only needs to meet the age and dFLC criterion
Who cannot take part
- Patients with a previous finding of amyloid in other biopsies will not be included
- Patients younger than 40 years of age are not eligible
- Adults unable to consent are not eligible, including the cognitively impaired Pregnant women, pregnant minors, minors (i.e., individuals who are not yet adults), wards of the state, non-viable neonates, neonates of uncertain viability, and prisoners are not eligible
Where in United States
- University of Alabama HospitalBirmingham, United StatesContact: Megan MaierTaking people
- Tufts Medical CenterBoston, United StatesContact: Denis ToskicTaking people
- Atrium Health Levine Cancer InstituteCharlotte, United StatesContact: Courtney SchepelTaking people
- The Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Naresh Bumma, MD (principal investigator)Taking people
- UT Southwestern, Harold C. Simmons Comprehensive Cancer CenterDallas, United StatesContact: Larry Anderson, MD (principal investigator)Not yet recruiting
- UNC Lineberger Comprehensive Cancer CenterDurham, United StatesContact: Kendall ConderTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Robert Vescio, MD (principal investigator)Taking people
- Columbia University Irving Medical CenterNew York, United StatesContact: CUIMC NavigatorsTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Khayla LeivaTaking people
- VCU Medical CenterRichmond, United StatesContact: Zackary MooreTaking people
- University of Utah, Huntsman Cancer HospitalSalt Lake City, United StatesContact: Sharmilee NuliTaking people
- University of California San FranciscoSan Francisco, United StatesContact: Ruixin SunTaking people
- Cleveland Clinic Florida, Weston HospitalWeston, United StatesContact: Chakra Chaulagain, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Screening for AL Amyloidosis in Smoldering Multiple Myeloma
- Plain-language title
- Screening people with smoldering multiple myeloma for early amyloidosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 October 2026